Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

Elena Ardini, Patrizia Banfi, Nilla Avanzi, Marina Ciomei, Paolo Polucci, Alessandra Cirla, Matteo D'Anello, Andrea Lombardi Borgia, Ilaria Motto, Cinzia Cristiani, Dario Ballinari, Eduard Felder, Daniele Donati, Arturo Galvani, Antonella Isacchi, Maria Menichincheri

Cancer Res (2018) 78 (13_Supplement): 4785.

https://doi.org/10.1158/1538-7445.AM2018-4785

Published: 01 July 2018

View article titled, Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

Journal Articles

Abstract 2810: Computationally predicted sensitivity of clinical cohorts identifies drug relationships and biomarkers associated with response to PCM-075, a PLK1 selective inhibitor

Penn Whitley, Peter J. Croucher, Barbara Valsasina, Dario Ballinari, Italo Beria, Jeffrey N. Miner, Mark G. Erlander

Cancer Res (2018) 78 (13_Supplement): 2810.

https://doi.org/10.1158/1538-7445.AM2018-2810

Published: 01 July 2018

View article titled, Abstract 2810: Computationally predicted sensitivity of clinical cohorts identifies drug relationships and biomarkers associated with response to PCM-075, a PLK1 selective inhibitor

Journal Articles

Abstract 805: NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML

Marina Ciomei, Elena Ardini, Gemma Texido, Rachele Alzani, Wilma Pastori, Dario Ballinari, Sabrina Cribioli, Fabio Gasparri, Nilla Avanzi, Daniele Casero, Daniele Donati, Arturo Galvani, Andrea Lombardi Borgia, Antonella Isacchi

Cancer Res (2018) 78 (13_Supplement): 805.

https://doi.org/10.1158/1538-7445.AM2018-805

Published: 01 July 2018

View article titled, Abstract 805: NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML

Journal Articles

Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models

Cancer Res (2017) 77 (13_Supplement): 2082.

https://doi.org/10.1158/1538-7445.AM2017-2082

Published: 01 July 2017

View article titled, Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models

Journal Articles

Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

Cancer Res (2017) 77 (13_Supplement): 5163.

https://doi.org/10.1158/1538-7445.AM2017-5163

Published: 01 July 2017

View article titled, Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

Journal Articles

Abstract 1223: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability

Alessia Montagnoli, Sonia Rainoldi, Antonella Ciavolella, Dario Ballinari, Francesco Caprera, Lucio Ceriani, Rosita Lupi, Marina Ciomei, Eduard Felder, Antonella Isacchi, Daniele Donati, Arturo Galvani, Gianluca Papeo

Cancer Res (2016) 76 (14_Supplement): 1223.

https://doi.org/10.1158/1538-7445.AM2016-1223

Published: 15 July 2016

View article titled, Abstract 1223: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability

Journal Articles

Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines

Patrizia Carpinelli, Marisa Montemartini, Nadia Amboldi, Dario Ballinari, Sabrina Cribioli, Marina Ciomei, Riccardo Colombo, Stefania Re Depaolini, Nilla Avanzi, Giulia Canevari, Walter Ceccarelli, Helena Posteri, Maria Gabriella Brasca, Daniele Donati, Eduard Rudolf Felder, Antonella Isacchi, Arturo Galvani, Alessia Montagnoli

Cancer Res (2016) 76 (14_Supplement): 3795.

https://doi.org/10.1158/1538-7445.AM2016-3795

Published: 15 July 2016

View article titled, Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines

Journal Articles

Abstract 1638: Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer

Riccardo Colombo, Mike Burbridge, Marianne Rodriguez, Frédérique Cantero, Marina Caldarelli, Maria Laura Giorgini, Francesco Sola, Dario Ballinari, Marina Ciomei, Roberta Bosotti, Alessia Montagnoli, Antonella Isacchi, Daniele Donati, Arturo Galvani

Cancer Res (2015) 75 (15_Supplement): 1638.

https://doi.org/10.1158/1538-7445.AM2015-1638

Published: 01 August 2015

View article titled, Abstract 1638: Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer

Journal Articles

Abstract 2851: Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor

Alessia Montagnoli, Gianluca Papeo, Sonia Rainoldi, Alessandra Cirla, Antonella Ciavolella, Clara Albanese, Michele Modugno, Roberta Bosotti, Alessio Somaschini, Giovanni Carapezza, Rosita Lupi, Dario Ballinari, Marina Ciomei, Enrico Pesenti, Daniele Donati, Antonella Isacchi, Arturo Galvani

Cancer Res (2015) 75 (15_Supplement): 2851.

https://doi.org/10.1158/1538-7445.AM2015-2851

Published: 01 August 2015

View article titled, Abstract 2851: Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor

Journal Articles

Abstract 74: Establishment and characterization of the new sacral chordoma cell line Chor-IN-1

Paola Magnaghi, Roberta Bosotti, Nadia Amboldi, Liviana Cozzi, Alessio Somaschini, Silvia Stacchiotti, Fabio Bozzi, Elena Tamborini, Elena Conca, Silvana Pilotti, Marco A. Pierotti, Sebastiano Di Bella, Carlo Cusi, Dario Ballinari, Arturo Galvani, Barbara Salom, Antonella Isacchi

Cancer Res (2015) 75 (15_Supplement): 74.

https://doi.org/10.1158/1538-7445.AM2015-74

Published: 01 August 2015

View article titled, Abstract 74: Establishment and characterization of the new sacral chordoma cell line Chor-IN-1

Journal Articles

Abstract 4539: NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer

Alessia Montagnoli, Maria Menichincheri, Nadia Amboldi, Dario Ballinari, Marina Ciomei, Francesco Fiorentini, Rosita Lupi, Daniele Pezzetta, Sonia Rainoldi, Daniele Pezzetta, Eduard Felder, Antonella Isacchi, Enrico Pesenti, Arturo Galvani

Cancer Res (2014) 74 (19_Supplement): 4539.

https://doi.org/10.1158/1538-7445.AM2014-4539

Published: 01 October 2014

View article titled, Abstract 4539: NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer

Journal Articles

Abstract 2097: Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase.

Riccardo Colombo, Marina Caldarelli, Maria Laura Giorgini, Anna Degrassi, Marina Ciomei, Daniele Pezzetta, Dario Ballinari, Alessia Montagnoli, Enrico Pesenti, Daniele Donati, Arturo Galvani

Cancer Res (2013) 73 (8_Supplement): 2097.

https://doi.org/10.1158/1538-7445.AM2013-2097

Published: 15 April 2013

View article titled, Abstract 2097: Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase.

Journal Articles

Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models.

Elena Ardini, Patrizia Banfi, Francesca Quartieri, Paolo Polucci, Nilla Avanzi, Dario Ballinari, Laura Mancini, Edward Felder, Daniele Donati, Arturo Galvani, Enrico Pesenti, Antonella Isacchi, Maria Menichincheri

Cancer Res (2013) 73 (8_Supplement): 2091.

https://doi.org/10.1158/1538-7445.AM2013-2091

Published: 15 April 2013

View article titled, Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models.

Journal Articles

Abstract 2940: Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death

Cancer Res (2012) 72 (8_Supplement): 2940.

https://doi.org/10.1158/1538-7445.AM2012-2940

Published: 15 April 2012

View article titled, Abstract 2940: Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death

Journal Articles

Abstract DD01-01: NMS-1116354: More than an inhibitor of Cdc 7 kinase in S-phase

Cancer Res (2010) 70 (8_Supplement): DD01-01.

https://doi.org/10.1158/1538-7445.AM10-DD01-01

Published: 15 April 2010

View article titled, Abstract DD01-01: NMS-1116354: More than an inhibitor of Cdc 7 kinase in S-phase

Journal Articles

Abstract #3737: A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models

Elena Ardini, Maria Menichincheri, Cristina De Ponti, Nadia Amboldi, Dario Ballinari, Maria Beatrice Saccardo, Valter Croci, Fabio Stellari, Gemma Texido, Paolo Orsini, Ettore Perrone, Tiziano Bandiera, Andrea Lombardi Borgia, Jaqueline Lansen, Antonella Isacchi, Francesco Colotta, Enrico Pesenti, Paola Magnaghi, Arturo Galvani

Cancer Res (2009) 69 (9_Supplement): 3737.

Published: 01 May 2009

View article titled, Abstract #3737: A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models

Journal Articles

Abstract #4685: Identification of a potent and specific inhibitor of Hsp90 showing in vivo efficacy.

Cancer Res (2009) 69 (9_Supplement): 4685.

Published: 01 May 2009

View article titled, Abstract #4685: Identification of a potent and specific inhibitor of Hsp90 showing in vivo efficacy.

Journal Articles

Abstract #3678: Nemorubicin-loaded DCBeads: in vitro characterization studies

Francesco Fiore, Paolo Cappella, Dario Ballinari, Maristella Colombo, Federico Riccardi Sirtori, Olga Valota

Cancer Res (2009) 69 (9_Supplement): 3678.

Published: 01 May 2009

View article titled, Abstract #3678: Nemorubicin-loaded DCBeads: in vitro characterization studies

Journal Articles

Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines

Cristina Geroni, Maria Antonietta Sabatino, Dario Ballinari, Marina Ciomei, Aurelio Marsiglio, Luigi Quintieri, Maura Floreani, Massimo Broggini

Cancer Res (2006) 66 (8_Supplement): 904.

Published: 15 April 2006

View article titled, Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines

Journal Articles

Antitumor efficacy of edotecarin in combination with other cytotoxic drugs.

Marina Ciomei, Valter Croci, Enrico Pesenti, Tsutomu Kodera, Yoshiaki Monden, Antonella Ciavolella, Dario Ballinari, Hiroharu Arakawa

Cancer Res (2004) 64 (7_Supplement): 483.

Published: 01 April 2004

View article titled, Antitumor efficacy of edotecarin in combination with other cytotoxic drugs.

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

Abstract 2810: Computationally predicted sensitivity of clinical cohorts identifies drug relationships and biomarkers associated with response to PCM-075, a PLK1 selective inhibitor

Abstract 805: NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML

Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models

Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

Abstract 1223: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability

Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines

Abstract 1638: Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer

Abstract 2851: Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor

Abstract 74: Establishment and characterization of the new sacral chordoma cell line Chor-IN-1

Abstract 4539: NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer

Abstract 2097: Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase.

Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models.

Abstract 2940: Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death

Abstract DD01-01: NMS-1116354: More than an inhibitor of Cdc 7 kinase in S-phase

Abstract #3737: A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models

Abstract #4685: Identification of a potent and specific inhibitor of Hsp90 showing in vivo efficacy.

Abstract #3678: Nemorubicin-loaded DCBeads: in vitro characterization studies

Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines

Antitumor efficacy of edotecarin in combination with other cytotoxic drugs.

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

AACR Journals
on Social Media